Transcriptional repression by the C-terminal binding protein (CtBP) is proposed to require nicotinamide adenine dinucleotide dehydrogenase (NAD(H). Previous studies have implicated CtBP in transcriptional repression of the p21 waf1/cip1 gene. Similarly, the NAD-dependent poly(adenosine diphosphate)ribose polymerase 1 (PARP1) may affect p21 expression via its NAD-dependent enzymatic activity; we therefore asked if PARP1 and CtBP were functionally linked in regulating p21 transcription. We found that restraint of basal p21 transcription requires both CtBP and PARP1. PARP inhibition attenuated activation of p21 transcription by both p53-independent and p53-dependent processes, in a CtBPdependent manner. CtBP1 þ 2 or PARP1 þ 2 knockdown partially activated p21 gene expression, suggesting relief of a corepressor function dependent on both proteins. We localized CtBP-responsive repression elements to the proximal promoter region, and found ZBRK1 overexpression could also overcome DNA damage-dependent, but not p53-dependent activation through this region. By chromatin immunoprecipitation we find dismissal of CtBP from the proximal promoter following DNA-damage, and that PARP1 associates with a CtBP corepressor complex in nuclear extracts. We propose a model in which both CtBP and PARP functionally interact in a corepressor complex as components of a molecular switch necessary for p21 repression, and following DNA damage signals activation of p21 transcription by corepressor dismissal and coactivator recruitment.
Introduction
C-terminal binding protein (CtBP) was originally identified as a binding partner for the E1A oncoprotein (Boyd et al., 1993) , and serves as a corepressor for a variety of cellular transcriptional repressors. Candidate gene targets were subsequently suggested from differential gene expression data by comparison of wild-type and CtBP isoform deficient mouse embryonic fibroblasts (MEFs; Grooteclas and Frisch, 2000; Grooteclas et al., 2003) , whereas immunoprecipitation and mass spectrometry analysis highlighted the diverse nature of the CtBP containing complex (Shi et al., 2003) . Although the biological implications of CtBP corepressor function at individual gene targets are not well described, data from CtBP knockout mice and Drosophila indicate the biological role of CtBP appears to be for controlling transcription pathways important in oncogenesis and essential developmental programs (Nibu et al., 1998; Hildebrand and Soriano, 2002; Bergman and Blades, 2006) .
The CtBP gene family (Boyd et al., 1993; Schaeper et al., 1995) consists of two widely expressed genes encoding three proteins (Furusawa et al., 1999; Sewalt et al., 1999 ) that bind to diverse repressor proteins through a PxDLS motif. The corepressor activity of the two major homologs (CtBP1 and CtBP2) is inferred from copurification with histone deacetylases and histone methyltransferases (Sundqvist et al., 1998; Shi et al., 2003) , and repression activity as a GAL4 fusion protein in UAS-dependent reporter assays. CtBP structurally resembles a 2-hydroxyacid dehydrogenase and some studies suggest that corepressor activity requires both NAD(H) binding and a proposed enzymatic activity (Zhang et al., 2002; Nardini et al., 2003) . The importance of these functions is unclear (Chinnadurai, 2007) , with NAD(H) binding and putative catalytic functions, including NAD-dependent dimerization (Balasubramanian et al., 2003) , important in some (Kumar et al., 2002) but not all experimental paradigms . NAD þ is also a substrate for poly(ADP)ribose polymerase 1 (PARP1) activated in response to DNA damage. PARP1 facilitates cellular responses and DNA repair by catalyzing poly(adenosine diphosphate (ADP)-ribosyl)ation of itself, histone and other proteins (Schreiber et al., 2006) . PARP1 also regulates transcription by affecting chromatin structure and may bind DNA directly to alter gene expression (Kim et al., 2004; Krishnakumar et al., 2008) either through its chromatin modifying enzymatic activity or by direct interactions with other transcriptional regulatory proteins (Ju et al., 2004; Ambrose et al., 2007) , similar to a co-activator and corepressor model of action. These findings demonstrate gene specific transcriptional control by PARP proteins. One proposed mechanism is for PARP1 to act as a switch, converting from a repressor to an activator following its activation (Ju et al., 2004) .
CtBP was implicated in p21 gene transcription by analysis of CtBP-dependent differential expression microarray data (Grooteclas et al., 2003) , suggesting that CtBP corepressor activity might restrain p21 expression. Interestingly, PARP enzymatic inhibition also attenuated p21 expression after g-IR (Wieler et al., 2003) , implying that either PARP directly or the consequences of PARP activity are required for p21 activation. The p21 promoter is activated by p53-dependent and -independent pathways during cytotoxic stress or DNA damage (Gartel and Radhakrishnan, 2005) and p53-independent activation required a BRCA1 activator function at the proximal promoter (Somasundaram et al., 1997) . Interestingly, CtBP has been shown to decrease BRCA1 mediated p21 activation (Li et al., 1999) and is recruited to BRCA1 by C-terminal interacting protein (CtIP). We hypothesized that CtBP and PARP might have a common functional link through NAD and cooperate in a switch between repression and activation of p21 transcription.
In this report, we demonstrate that CtBP is required for the attenuation of p21 activation observed with PARP inhibitors suggesting a functional interaction between CtBP and PARP in restraint of basal p21 expression and activation in response to DNA damage. CtBP restrained both p53-dependent and p53-independent p21 activation, and in the absence of CtBP, activation of p21 does not require PARP activity. We found CtBP1 localized to the proximal p21 promoter by chromatin immunoprecipitation, and demonstrated the CtBP-dependent element mapped within a region important for p53-independent activation by promoter reporter assays. These data suggest a model in which both PARP and CtBP cooperate in, and are necessary for maintenance of a repression complex at the proximal promoter, with PARP activity subsequently participating in p21 promoter activation in part through CtBP corepressor dismissal.
Results

PARP inhibitor attenuation of activated p21 expression requires CtBP
Previous studies independently suggest that PARP (Wieler et al., 2003) and CtBP (Grooteclas et al., 2003) are among the many factors implicated in regulation of the p21 promoter. Because of a link between CtIP recruitment and p21 transcriptional activation (Li et al., 1999) and a potential role for NAD in CtBP function, we asked if there was a functional link between the CtBP corepressor and PARP activity in p21 expression.
We first examined the effects of PARP inhibition on p21 expression in LNCaP cells following different methods of DNA damage pathway activation. Both ultraviolet C (UV-C) and hydrogen peroxide (H 2 O 2 ) induced poly(ADP)-ribose accumulation (Supplementary Figure S1 ), and UV-C activation of p21 mRNA accumulation was attenuated by pretreatment with the PARP inhibitors, 3-aminobenzamide ( Figure 1a ) and PJ34 (Figure 1b) , at 6 and 18 h. These results were replicated in other cell lines (U2OS, HeLa, H1299 and MEFs) with adriamycin, g-IR and H 2 O 2 , demonstrating PARP-dependence across the various pathways for p21 activation (for example Figures 2a and 7 , and data not shown). These treatments did not alter CtBP1 or CtBP2 protein levels (Figures 1a, b and 3, Supplementary Figure S4 ). PARP inhibition did not alter stabilization of p53 or serine-15 (p53 pSer15 ) phosphorylation, demonstrating that PARP inhibition does not impede UV-C induced ATR-dependent p53 activation (Figures 1a, 2b ; Canman et al., 1998) .
We next asked whether CtBP mechanistically operated in PARP-dependent p21 transcriptional activation, employing MEFs from CtBP1/CtBP2 double knockout embryos (Hildebrand and Soriano, 2002) . In contrast to heterozygous CtBP1 þ /À /CtBP2 þ /À MEFs, PARP inhibition did not attenuate p21 activation in homozygous CtBP1
À/À MEFs (Figure 2a ). PARP inhibitor attenuation of H 2 O 2 -induced p21 activation also depended on CtBP (Supplementary Figure S2) , suggesting a common mechanism among different p21 activation pathways. Relative PARP1 (Supplementary Figure S3 ) and CtBP1 ( Figure 2b ) protein levels remained unchanged in these MEFs, whereas p53 was activated (p53 pSer15 ) following UV-C treatment (Figure 2b ). Following UV-C, adriamycin or g-IR, CtBP1 remains nuclear in CtBP1
þ /À MEFs, U2OS and H1299 cells (Figure 2c , Supplementary Figure S4 ). These experiments implicate PARP in p21 activation, and demonstrate that in the absence of CtBP, activation of p21 does not require PARP activity.
One model proposed for regulation of CtBP-dependent corepression is rapid nuclear export and proteosomal degradation following UV-B exposure (Zhang et al., 2005) . CtBP steady state levels and subcellular localization did not change in our initial experiments in response to UV-C (Figures 1, 2 , Supplementary Figure  S4 ). We performed a dose ranging experiment with UV-C dose equivalents (Takasawa et al., 2005) , to determine whether CtBP degradation could account for the loss of repression. This experiment included energy (4500 J/m 2 ) sufficient to induce DNA double strand breaks and decrease steady state b-actin mRNA (Figure 3a , lower panel), and demonstrated appropriate increases in p53 protein and p21 mRNA, whereas CtBP levels remained unchanged after 6 (Figure 3a , upper panel) or 24 h (Supplementary Figure S5 ). An extended time course (50 J/m 2 ; 48 h) revealed no alteration in CtBP1 levels ( Figure 3b ) and shows the expected p53-dependent (U2OS, LNCaP) and p53-independent (H1299) p21 activation (Figure 3c ). Other DNA damage agents also did not influence CtBP levels (H 2 O 2 , adriamycin and g-IR; Figures 1, 2 , 4f, Supplementary Figure S4 ) or subcellular localization, with CtBP remaining predominately nuclear 24 h post-treatment (UV-C, adriamycin, g-IR and H 2 O 2 ) in U2OS, LNCaP, HeLa, H1299 and CtBP MEFs (Figure 2c and Supplementary Figure S4) . We conclude that in contrast to reports of rapid UV-B induced CtBP proteosomal degradation (Zhang et al., 2005) , steady state CtBP levels do not change following oxidative-, radiation-, or UV-induced DNA damage and therefore this is not a primary mode of regulation of the CtBP corepressor in this induction mechanism.
CtBP acts as a corepressor for p53-independent and -dependent p21 activation at the proximal promoter We found UV-C activated p21 in both p53-sufficient (U2OS, LNCaP) and p53-deficient cells (H1299; Figure 3c ). We next asked whether PARP and CtBP cooperate in restraint of activation in both p53-dependent (El Deiry et al., 1993) and p53-independent (Ocker and Schneider-Stock, 2007) mechanisms.
Previous studies have indicated that p53-independent activation of p21 in response to UV is mediated through promoter proximal elements (Haapaja¨rvi et al., 1999) . Both transient expression of a p53 expression plasmid and UV-C treatment activated a full-length (2.3 kbp) p21 promoter reporter in p53-deficient H1299 cells (Figure 4b , p21-luciferase (luc)), whereas a truncated construct lacking distal p53 sites (À349 to þ 1; p21(À349)-luc) responded to only UV-C and not p53. A minimal construct (À93 to þ 1; p21(À93)-luc;) did not respond to either UV-C or transfected p53. The specificity of the p53 response is shown by activation of a multimerized p53 response element (RE) promoter reporter by co-transfected p53, but not by UV-C (Figure 4c ). These results identify the region between À93 and À349 in the p21 promoter 5 0 flanking region as important for p53-independent p21 activation in response to UV-C, consistent with previous studies in p53-deficient MEFs (Haapaja¨rvi et al., 1999) . PARP inhibition reduced p53-independent UV-C activation of the transfected p21 promoter reporter by B30-75% (Figure 4d ), similar to the endogenous p21 promoter in a native chromatin context (Figure 1 ), whereas basal expression was not significantly affected ( Figure 4d , left bars).
We next examined CtBP-dependent corepression at the p21 promoter. Co-transfection of both CtBP1 and CtBP2 modestly, but significantly reduced both p53-independent (Figure 5a , left) and p53-dependent (Figure 5a , middle) activation, as well as basal expression (Figure 5b ) from the full-length p21 promoter reporter by B25%. Expression of CtBP with a mutation that abrogates PxDLS binding (CtBP1-A52D; Nardini et al., 2003) , but retains ability to act as a repressor as a GAL4 fusion (Supplementary Figure S6) , failed to repress p21 promoter activation. The CtBP1-A52D protein modestly enhanced activation by UV-C (Figure 5a ), suggesting a dominant-negative activity (described below). Neither CtBP1 nor CtBP2 reduced activation from the p53RE-luc reporter by p53 (Figure 5a , right). Taken together, these data suggest CtBP functions as a corepressor for a promoter proximal factor that blocks both p53-dependent and -independent pathways of p21 promoter activation, and that PARP activity leads to derepression through this region.
Previous studies have additionally mapped a BRCA1-regulated element to this proximal region of the p21 promoter (Somasundaram et al., 1997) , and suggest that CtBP may repress BRCA1-dependent transactivation of the p21 promoter in a corepressor complex including the BRCA1-interacting protein CtIP (Li et al., 1999) . ZBRK1, a zinc-finger KRAB domain repressor DNA binding protein (Zheng et al., 2000) likely directs this complex to this region. ZBRK1 contains a C-terminal BRCA1-dependent binding and repression domain (Tan et al., 2004) and has a putative DNA binding site at À322 to À318 (Lee et al., 2007) . Overexpressed ZBRK1 significantly repressed p53-independent, but not p53-dependent, activation of a p21 promoter reporter ( Figure 5c ). Collectively, these experiments demonstrate p53-independent p21 activation is repressed by elements in the proximal promoter, through CtBP, and is reversed by PARP activity. ZBRK1 repression of p53-independent p21 activation provides a potential candidate for a DNA binding protein upon which CtBP might be recruited. 
/CtBP2
À/À MEFs. Therefore, we asked whether CtBP reintroduction into these cells was sufficient to restore p21 repression. Wildtype or mutant CtBP isoforms were reexpressed in CtBP1
À/À MEFs via lentiviral transduction. Lentiviral expressed CtBP1 and CtBP2 were predominately nuclear (Figure 6a ), similar to endogenous CtBP1 ( Figure 2c ) and in partial contrast to transfected CtBP1 (Supplementary Figure S7 ; Verger et al., 2006) . Lentiviral expressed CtBP levels were similar to those measured endogenously (Supplementary Figure S8) . CtBP1 À/À /CtBP2 À/À MEFs had significantly higher level of basal p21 mRNA than the heterozygous CtBP1
Relative p21 ) or adriamycin (0.2 mg/ml) and immunostained after 18 h. Predominately, nuclear distribution is maintained following either UV-C or adriamycin compared with the untreated controls. Homozygous null MEFs (CtBP1 À/À /CtBP2 À/À ) are negative for CtBP1. 4 0 -6-diamidino-2-phenylindole staining identifies nuclei. Figure S2 ). CtBP1 or CtBP2 reconstituted MEFs significantly reduced basal p21 expression to levels below that observed in CtBP1 (Figure 6b ). Interestingly, CtBP deficient MEFs reconstituted with CtBP1-A52D had a significantly increased basal p21 mRNA level, possibly through a dominant negative effect of titrating away other corepressor proteins, similar to results from transient repression assays (Figure 5a ). Chromatin immunoprecipitation analysis demonstrated the association of CtBP with the proximal p21 promoter, but not the distal p53-responsive elements (Figure 6c ). Following p21 activation by H 2 O 2 , CtBP was dismissed with increases in acetylated histone H4 and RNA polymerase II recruitment, consistent with activated transcription. Because PARP activity and CtBP corepressor function appeared interdependent, we asked whether CtBP and PARP might coexist in a complex. Immunoprecipitation of CtBP1 (Figure 6d ) from nuclear extracts of CtBP1 reconstituted CtBP1
À/À MEFs (C90:CtBP1wt) recovered a complex including PARP1 and as well as two known CtBP binding partners, ZEB2 and CoREST (Shi et al., 2003) . Final, CtBP1 but not CtBP1-A52D reconstituted MEFs restored PARP inhibitor attenuation of p21 activation as compared with CtBP1 We performed the reciprocal experiment and also asked whether the presence of PARP protein was required for p21 basal repression. We determined the relative contribution of PARP1 and PARP2 to activation by constructing PARP or CtBP RNA interference knockdown cell lines via lentiviral transduction of small-hairpin RNA expression vectors. In HeLa cells, we achieved nearly 99% knockdown of CtBP1 and/or 2 and PARP1 protein (Figure 7a ). CtBP1 and CtBP2 knockdown did not alter the expression of PARP1, nor did the PARP1/PARP2 knockdown affect CtBP1 or CtBP2 expression (Figure 7a, right) .
Knockdown of CtBP1 but not CtBP2 released steady state repression, whereas the CtBP1 and CtBP2 double knockdown resulted in larger increases in basal p21 mRNA (fourfold; Figure 7b , top left). Interestingly, PARP1 and PARP2 knockdown also increased basal p21 mRNA levels (Figure 7b, bottom left) .
Following activation, p21 increased by the same relative degree (two-to three-fold) for both CtBP and PARP knockdown lines (Figure 7b, right panels) . The absolute p21 activation in CtBP1/CtBP2 double knockdown cell line was significantly greater than wild-type HeLa cells (Figure 7b, top right) . A similar additive effect was found in the PARP1/PARP2 double knockdown cell lines (Figure 7b , bottom) although p21 activation was significantly enhanced in each PARP knockdown cell line compared with wild-type cells. Both the CtBP1/CtBP2 knockdown and PARP1/PARP2 knockdown cell lines were insensitive to PARP inhibitor attenuation of p21 activation (Figure 7c) , similar to what we observed for CtBP1
À/À /CtBP2
À/À MEFs ( Figure 2a ). From these experiments we conclude that PARP1 and PARP2 together are necessary for PARPdependent activation of the p21 promoter and that PARP may comprise a repression complex with CtBP at the p21 promoter under basal conditions.
Discussion
In this study, we demonstrate that repression of basal p21 waf1/cip1 transcription requires both CtBP and PARP proteins, and that activation of PARP enzymatic activity is necessary for p21 promoter activation, by relief of repression, for both p53-dependent and -independent pathways. In this model, a CtBP-dependent repression complex exerts a dominant inhibitory influence over p21 transcription and must be dismissed by PARP activation before other promoter-directed activators may influence transcription (Figure 8) .
How does the corepressor CtBP specifically regulate transcription of the p21 gene? Previous studies implicated the CtIP in regulating BRCA1-dependent transactivation of the p21 promoter (Li et al., 1999) . In this model, phosphorylation of BRCA1 in response to DNA damaging agents disrupts binding of a repressive CtIP/ CtBP complex. In a similar model, a BRCA1/CtBP/ CtIP corepressor complex regulates the angiopoietin-1 promoter through recruitment by ZBRK1 (Furuta et al., 2006) . Our data indicate DNA damaging treatments induce p21 via a p53-independent, PARP-sensitive control element that resides within the first 350 nucleotides of the p21 promoter, corresponding to a proposed ZBRK1 binding site at À322 to À318 (Figures 4 and 5; Lee et al., 2007) . This region also harbors a histone deacetylase sensitive region (Wilson et al., 2008; Mottet et al., 2009) , and previous studies have demonstrated that BRCA1 trans-activates the p21 promoter through elements located within the proximal promoter region (Somasundaram et al., 1997) . We found that ZBRK1 acted as a repressor of p21 transcription (Figure 5c ), and that CtBP repressed p21 promoter activity through an overlapping region (Figure 5a ). Collectively, these data suggest a hypothesis that CtBP may be recruited to the p21 promoter via ZBRK1, possibly indirectly through the BRCA1/CtIP complex. Recent studies have defined a role for PARP in genespecific regulation, in both activation and repression mechanisms (reviewed by Kraus, 2008) . Our data suggest that PARP serves a dual role at the p21 promoter, as an intrinsic component of a repressor complex under basal conditions, with poly(ADP-ribosyl)ation enzymatic activity necessary for transcriptional activation. PARP knockdown increases basal p21 expression (Figure 6b ), an effect also noted in PARP1 deficient embryonic stem cells (Ogino et al., 2007) , consistent with loss of a repressor function for this promoter. Inhibition of enzymatic activity precludes robust activation, but does not detectably alter basal p21 transcription.
PARP enzymatic activity and the coregulatory role of PARP at a promoter may have variable functions, depending on the gene-specific context. For example, the presence of PARP1 is associated with AP-2a expression while its enzymatic activity contributed to repressing transcription (Li et al., 2004) . At the MASH1 promoter, occupancy by PARP1 as a component of the Gro/TLE1 corepressor complex is associated with repression, but upon enzymatic activation turns on transcription by promoting an exchange for co-activators (Ju et al., 2004) . In contrast, retinoic acid-dependent transcription requires PARP as a ligand-dependent co-activator independent of enzymatic activity (Pavri et al., 2005) . In another variation, both PARP inhibitors and PARP1 knockdown promoted bcl6 gene expression in parallel (Ambrose et al., 2007) , whereas both pharmacological inhibition and knockdown inhibited the CXCL1 promoter (Amiri et al., 2006) .
Although our data suggest PARP1 may be the predominant form interacting with CtBP biochemically, these data also suggest that PARP2 may be involved. We find reducing PARP2 has a significant effect alone in increasing p21 and has an additive effect on both basal and stimulated transcription in conjunction with knockdown of PARP1 (Figure 7b ). PARP1 and PARP2 form dimers in vitro (Schreiber et al., 2002) and may account for functional interaction between these different PARP forms at this promoter. Both PARP and the poly(ADP-ribosyl)ation enzymatic activity of PARP have been proposed to determine a coregulatory protein exchange mechanism at specific promoters in response to pathways not typically associated with PARP1 activation. The Gro/ TLE corepressor maintains repression of the MASH1 promoter and has been biochemically demonstrated to include PARP1 (Ju et al., 2004) . At this promoter, knockdown of PARP1 leads to derepression of transcription suggesting an intrinsic repressor function. In a manner similar to regulation of CtBP-dependent corepression of the p21 promoter, CaMKII-dependent transcriptional activation requires PARP enzymatic activity, possibly leading to poly(ADP-ribosyl)ation and dismissal of components of the corepressor complex (Ju et al., 2004) . PARP1 has also been shown to be necessary for retinoic acid-dependent activation of transcription (Pavri et al., 2005) by converting a resident inactive mediator to an active state, however in this role, PARP1 enzymatic activity is dispensable. In both these complexes, PARP serves a regulatory role in switching a repressive complex to an activator. How might PARP and CtBP functionally interact? CtBP has been proposed to require NAD for corepressor activity (Zhang et al., 2002; Nardini et al., 2003) , raising the intriguing possibility that PARP and CtBP may interact through this metabolic coenzyme. A similar functional interdependence has been proposed between PARP and SIRT1 (Kolthur-Seetharam et al., 2006) , with depletion of NAD through activation of each altering the function of the other. PARP-dependent depletion of NAD could alter either a proposed intrinsic dehydrogenase activity (Nardini et al., 2003) or alternatively NAD-dependent dimerization (Balasubramanian et al., 2003) leading to disruption of CtBP corepressor complex formation.
CtBP may also serve to regulate PARP activity through alteration of the relative ratio of NAD:NADH, although a catalytic function (or substrate) for CtBP as a dehydrogenase has not yet been described. Alternatively, PARP may alter CtBP-dependent repression by ADP-ribosylation of proteins within the CtBP corepressor complex. Poly(ADP)ribose acceptor sites in PARP1 are specific for glutamate, aspartate (Tao et al., 2009) or lysine (Altmeyer et al., 2009) residues and CtBP has a glutamate (E295) at its proposed dehydrogenase site (Kumar et al., 2002; Nardini et al., 2003) . We attempted to identify poly(ADP-ribosyl)ation of CtBP by a sequential immunoprecipitation-western approach, but did not detect modification (not shown). We do not see a shift in the size of CtBP with activation as might be expected for poly(ADP-ribosyl)ation (Figures 1-3) , however, the amount of PARP in association with CtBP may be small, and the extent of modification may be limited.
Collectively, our data support a model (Figure 8 ) where p21 activation following a DNA damage stimulus requires sequential activation of PARP1/2 followed by CtBP1 dismissal, converting the repression complex to allow for recruitment of transcriptional activators. In this model, PARP may constitute a transcription switch, linked to CtBP via NAD as a common cofactor.
Materials and methods
Cell culture
Cell lines were passage within 24 h before experiments. U2OS, H1299, HeLa, MCF, CtBP null (C90) and heterozygote (C86) MEFs (Dr J Hildebrand, University of Pittsburgh, Pittsburgh, PA, USA) and all lentiviral cell lines were grown with 10% fetal calf serum in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) with selection antibiotics when necessary. LNCaP cells were grown in 10% fetal calf serum/RPMI. Lentiviral expression and small interfering RNA vectors, lentiviral stable cell lines Lentiviral transfected cell lines were created using a modified vector system (Invitrogen). Viral production was according to standard techniques in HEK293T cells.
Stable human wild-type or mutant CtBP reexpression cell lines were constructed from CtBP1
À/À MEFs using lentiviruses containing the Tet-ON promoter (5 0 -CCCTATCA GTGATAGA-3 0 ; Moyed and Bertrand, 1983) , dominant selection markers and either FLAG-CtBP1 or myc-CtBP2 cloned into the lentiviral expression vectors. Both clonal and pooled cell lines had similar transgene protein expression.
Stable shRNA knockdown cell lines were constructed using lentiviruses harboring the human H1 promoter, a shRNA (n19), loop and (T 6 ) terminator sequence. Multiple sequences and cell lines were screened for each; the shRNA used for the data presented are CtBP1: 5 0 -CGACTTCACCGTCAAGC AG-3 0 , CtBP2: 5 0 -ATCCACGAGAAGGTTCTAA-3 0 , PARP1 5 0 -GCCTCCGCTCCTGAACAAT-3 0 (Kameoka et al., 2004) , PARP2 5 0 -TGGGAGTACAGTGCCATTA-3 0 . Knockdown was evaluated by western blot for protein (CtBP1, CtBP2 and PARP1) or for mRNA by reverse transcription PCR (PARP2; primers: forward 5 0 -TTAGAAGATGATGCCCAGAG GAAC-3 0 , reverse 5 0 -GCCTTGATTTGTGCCACTGTCAG-3 0 ). UV-C, g-IR and drug treatment 3-Aminobenzamide (3-AB; 2.5-5 mM) and PJ34 (25-75 mM; EMD Biosciences, Gibbstown, NJ, USA), adriamycin (0.2 mg/ml; Sigma, St Louis, MO, USA) and hydrogen peroxide (250 mM)
were diluted in growth media directly before use. PARP inhibitors were added 1 h before further treatments and left in the media for the indicated experiment length. For UV treatment, the media was removed, cells exposed to UV-C Immunofluorescence Cells were fixed in 4% paraformaldehyde, permeabilized in 0.1%Triton-X100 and immunostained (3%NGS:PBS) with antibodies for CtBP1 (C1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), FLAG (M2) and c-myc (9E10; Sigma) and fluorescent secondary antibodies (Invitrogen), followed by 4 0 -6-diamidino-2-phenylindole. For poly(ADP)-ribose (10 H; Alexis Biocehmicals; Plymouth Meeting, PA, USA), cells were fixed in 1:1 cold acetone:methanol and immunostaining performed.
Western blot analysis and antibodies For whole cell extract preparation, cells were harvested in cold lysis buffer (50 mM HEPES pH7.4, 250 mM NaCl, 10 mM NaF, 0.2 mM EDTA, 0.5% NP-40 plus protease inhibitors (Sigma)), cellular debris pelleted and supernatant used for western blots. For immunoprecipitation, cells were harvested into lysis buffer (50 mM HEPES (pH 7.5) 10 mM KCl, 0.2 mM EDTA, 0.5% NP-40, 1 mM DTT, 250 mM NaCl plus protease inhibitors), the supernatant cleared, brought to 150 mM NaCl, incubated with primary antibodies (anti-FLAG), then Protein-A Sepharose (Sigma), washed extensively and western blots was performed. Antibodies: anti-tubulin (b-5-1-2, Sigma), FLAG (M2, Sigma), p53 (Bp53-12 or FL-393; Santa Cruz Biotechnology), p21 (F-5; Santa Cruz Biotechnology), phospho-p53(Ser15; Cell Signaling; Danvers, MA, USA), CtBP1 (C-1, E12 or H-440; Santa Cruz Biotechnology), CtBP2 (BD Biosciences, San Jose, CA, USA), PARP-1 (C2-10; BD Pharmigen), Zeb2 (H-102, Santa Cruz Biotechnology), CoR-EST (BD Biosciences). Secondary antibodies were conjugated with chromophores or horseradish peroxidase (Invitrogen).
Quantitative real-time PCR and semi-quantitative PCR RNA was isolated from cultured cells by Trizol (Invitrogen), chloroform extracted and isopropanol precipitated. Equal amounts of RNA were used for complementary DNA synthesis (Promega, Madison, WI, USA) and standardized spur (semi-quantitative) reactions analyzed on ethidium stained agarose gel electrophoresis and quantified by densitometry (Imager-FX, Bio-Rad, Hercules, CA, USA). Primers: human p21 (forward: 5 0 -ATGT CAGAACCGGCTGGGGATGTC-3 0 , reverse 5 0 -GGGCTTC CTCTTGGAGAAGATC-3 0 ), mouse p21 (forward: 5 0 -CCAA TCCTGGTGATGTCCG-3 0 , reverse: 5 0 -CGCTTGGAGTGA TAGAAATCTG-3 0 ) and mouse and human b-actin (forward: 5 0 -GATGGAGCCGCCGATCCACACGG-3 0 , reverse 5 0 -CTA CGTCGCCCTGGACTTCGAGC-3 0 ). Conditions that provided a signal within the linear range of detection were used for each primer set.
Real time PCR (Taq-Man, Applied Biosystems; Foster City, CA, USA) was performed with p21 and b-actin probes per manufacturer's instructions. The reaction products were analyzed by calculating the relative, normalized target gene expression in the low exponential range (Pfaffl, 2001) . Each experiment with separately treated, triplicate samples was performed at least twice, graphed as a s.e.m., relative to control samples. Statistical analyses utilized two-tailed t-test, 95% confidence interval.
Chromatin immunoprecipitation
In brief, pooled, treated cells were crosslinked with formaldehyde, lyses, sonicated and cleared, input samples removed for analysis and the cell lysates incubated overnight at 4 1C with the indicated antibodies. Salmon sperm treated protein-A agarose beads were added for 1 h followed by low-and highsalt buffer washes according to the manufacturer's protocols (Millipore, Billerica, MA, USA). Chromatin was eluted (1% SDS, 50 mM NaHCO 3 , 250 mM NaCl, 20 mg/ml proteinase K), the crosslinks reversed (65 1C, 12 h) and the DNA products phenol:chloroform extracted and ethanol precipitated. PCR at the p21 promoter was performed for a fragment encompassing 279 base pair region overlapping the TATA box (forward: 5 0 -GTGCTGTGTCCTCCTGGAGAGTGCCAACTCATTCTC C-3 0 reverse: 5 0 -CGACCCGCGCTCGGCCCACCGCGCC G-3 0 ), and 318 nucleotides overlapping the primary p53 RE (forward: 5 0 -CCATGCTGCTCCACCGCACTCTGG-3 0 , reverse: 5 0 -CCTGTCGCAAGGATCCTGCTGG-3 0 ). Antibodies: CtBP1 (C-1, Santa Cruz Biotechnology), RNA polymerase II (N-20, Santa Cruz Biotechnology), acetyl-histone H4 (Millipore).
Plasmid construction, transfections and P21 reporter luciferase assays Human CtBP1 and CtBP2 constructs were PCR tagged in pcDNA3 with either a 2XFLAG or human c-my epitopes. Point mutations were created by oligonucleotide mutagenesis. ZBRK1 (ATCC; Manassas, VA, USA) was PCR inserted into 2XFLAG/pcDNA3. A full-length (2.3 kbp 5 0 flanking DNA) p21 promoter-luciferase reporter and deletions were constructed by PCR in pGL3-luc (Promega, Madison, WI, USA). The p53-RE luciferase construct was created by direct tandem oligonucleotide Figure 8 Model of CtBP and PARP effects on p21 repression and activation. Activation of PARP activity by oxidative injury or UV damage leads to dismissal of the CtBP corepressor complex and permits recruitment of a co-activator complex. In the absence of CtBP, DNA-damage activates p21 irrespective of PARP activity, but in the presence of CtBP, PARP activity is necessary for removal of the corepressor complex.
UV or peroxide
ligation of either wild-type or mutant p53RE (Kern et al., 1992) upstream of a minimal TATA sequence. Transfections for immunofluorescence and luciferase assays used Trans-IT (Panvera, Madison, WI, USA). For luciferase assays: reporter constructs were co-transfected with a Renilla-luciferase control vector (Promega; 10 ng) and pcDNA3 to equalize the DNA amount using. For drug experiments, 18 h following transfection fresh media containing PARP inhibitors was added and cells harvested after 18 h. For UV experiments, 18 h following transfection, cells were either preincubated for 1 h with PARP inhibitors or in media alone and UV-C (50 J/m 2 ) exposed. Luciferase assays were performed on triplicate samples. Data are plotted using a single average ratio of three Firefly:Renilla ratios.
